IMPORTANT GENOCEA BIOSCIENCES, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP Announces that a Securities Class Action Lawsuit has been Filed on Behalf of Investors who Purchased and Suffered Losses in Genocea Biosciences, Inc.
Lead Plaintiff Deadline is January 2, 2018
NEW YORK, NY / ACCESSWIRE / November 14, 2017 / Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts against Genocea Biosciences, Inc. (“Genocea” or the “Company”) (NASDAQ: GNCA). and certain Company executives on behalf of investors who purchased or otherwise acquired Genocea Biosciences, Inc. securities between May 5, 2017 and September 25, 2017, inclusive (the “Class Period”).
Investors who have incurred losses in Genocea Biosciences, Inc. are urged to contact the firm immediately at email@example.com or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.
If you have incurred losses in the securities of Genocea Biosciences, Inc. and would like to assist with the litigation process as a lead plaintiff, you may, no later than January 2, 2018, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in Genocea Biosciences, Inc.
The filed complaint alleges that throughout the Class Period, the defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. It is alleged that defendants made false and/or misleading statements and/or failed to disclose that
the Company’s finances were insufficient to support Phase 3 trials of GEN-003;
accordingly, Genocea had overstated the prospects for GEN-003; and
as a result of the foregoing, Genocea’s public statements were materially false and misleading at all relevant times.
On September 25, 2017 after the market closed, Genocea disclosed that it was halting spending and activities on GEN-003, its lead product candidate, and exploring strategic alternatives for the drug. The Company also announced that it was cutting 40% of its workforce.
On the subsequent trading day following this news, Genocea’s share price fell $4.08 per share, or 76.5%, to close at $1.25 per share on September 26, 2017.
Wolf Haldenstein Adler Freeman & Herz LLP has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at firstname.lastname@example.org, or visit our website at www.whafh.com.
Attorney Advertising. Prior results do not guarantee or predict a similar outcome.
SOURCE: Wolf Haldenstein Adler Freeman & Herz LLP